Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Heinzmann

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|December 10, 2015
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancerAngelica L Quartino, Carina Hillenbach, Jing Li, et al.
Cancer Reports (Hoboken, N.J.)|January 25, 2022
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapyCristina Julian, Robson J M Machado, Sandhya Girish, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesChris J Wynne, Rod B Ellis-Pegler, Devonie S Waaka, et al.
Journal for Immunotherapy of Cancer|November 14, 2025
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data martDavid F Lamparter, Virginia C Schmid, Rajat Mohindra, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-upChristian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
The Lancet. Oncology|March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|December 10, 2015
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancerAngelica L Quartino, Carina Hillenbach, Jing Li, et al.
Cancer Reports (Hoboken, N.J.)|January 25, 2022
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapyCristina Julian, Robson J M Machado, Sandhya Girish, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesChris J Wynne, Rod B Ellis-Pegler, Devonie S Waaka, et al.
Journal for Immunotherapy of Cancer|November 14, 2025
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data martDavid F Lamparter, Virginia C Schmid, Rajat Mohindra, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-upChristian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, et al.
The Lancet. Oncology|March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Pageof 2